Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Early Ovarian Tumor Detection Discovery to Aid Development of Screening Test

By LabMedica International staff writers
Posted on 25 May 2010
Ovarian cancer kills nearly 15,000 women in the United States alone each year, and less than half of the women diagnosed with the disease survive five years. More...
A screening test that detects ovarian cancer early, when it is still treatable, would have the potential of reducing the high mortality, yet scientists have not known where the tumors originate or what they look like. Now, researchers believe they have solved both obstacles.

New research, published on April 26, 2010, in the journal in PLoS ONE, revealed that researchers from Fox Chase Cancer Center (Philadelphia, PA, USA) have uncovered early tumors and precancerous lesions in cysts that fold into the ovary from its surface, called inclusion cysts. "This is the first study giving very strong evidence that a substantial number of ovarian cancers arise in inclusion cysts and that there is indeed a precursor lesion that you can see, put your hands on, and give a name to,” stated Jeff Boyd, Ph.D., chief scientific officer at Fox Chase and lead author on the study, which also involved colleagues at Memorial Sloan-Kettering Cancer Center (New York, NY, USA). "Ovarian cancer most of the time seems to arise in simple inclusion cysts of the ovary, as opposed to the surface epithelium.”

Clinicians and researchers have been looking for early ovarian tumors and the precancerous lesions from which they develop for years without success. In this study, Dr. Boyd and colleagues used a combination of conventional microscopy and molecular approaches to reveal the early cancers.

"Previous studies only looked at this at the morphologic level, looking at a piece of tissue under a microscope,” Dr. Boyd said. "We did that but we also dissected away cells from normal ovaries and early stage cancers, and did genetic analyses. We showed that you could follow progression from normal cells to the precursor lesion, which we call dysplasia, to the actual cancer, and see them adjacent to one another within an inclusion cyst.”

To learn where and how the tumors arise, the team examined ovaries removed from women with BRCA mutations, who have a 40% lifetime risk of developing ovarian cancer, and from women without known genetic risk factors. In both groups, the researchers discovered that gene expression patterns were considerably different in cells in the inclusion cysts compared to the normal surface epithelium cells, including increased expression of genes that control cell division and chromosome movement.

Moreover, when the investigators used a technique called fluorescence in-situ hybridization (FISH), which can be used to identify individual chromosomes in cells, they noticed that cells from very early tumors and precursor lesions frequently carried extra chromosomes. In fact, the team found that 9% of the normal cells isolated from the cysts had extra chromosomes, even though the tissue appeared completely benign under the microscope. By contrast, virtually none of the cells isolated from the surface of the ovary, which was previously believed to be the site of early ovarian cancers, carried extra chromosomes.

With these new data on the origin of ovarian cancer, Dr. Boyd and others can now begin to develop screening tests, perhaps based on molecular imaging, which could be utilized to detect early ovarian cancers in asymptomatic women.

Related Links:

Fox Chase Cancer Center
Memorial Sloan-Kettering Cancer Center



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.